CLINICAL TRIAL PATIENT TECHNOLOGY INSIGHTS
-
Edge AI Is Reshaping How Clinical Trials Run
Edge computing and AI are transforming clinical trials – enabling real time monitoring, decentralized research, and faster, more cost-effective drug development.
-
Telehealth In Clinical Trials: What Sites And Patients Think
Sites and patients have complicated views on telehealth in trials. Here’s what the evidence shows about who benefits, who bears the burden, and where the limits are.
ECOA RESOURCES
-
Explore how to ensure that clinical trials are truly patient-centered, and why it is critical to do so.
-
Explore the reasons why accessibility stands as a crucial pillar for the prosperity of biopharmaceutical and clinical research, having evolved into an all-encompassing industry imperative.
-
Discover how DCTs leverage “virtual” tools, such as telemedicine, sensory-based technologies, wearable medical devices, and direct delivery of study drugs and materials to patients’ homes.
ECONSENT RESOURCES
-
Support the digitization of the participant consent process and begin creating multimedia-enhanced electronic informed consent forms (eICFs) that participants sign electronically, eliminating burdensome and error-prone paper-based processes.
-
Discover how DCTs leverage “virtual” tools, such as telemedicine, sensory-based technologies, wearable medical devices, and direct delivery of study drugs and materials to patients’ homes.
-
This on‑demand session offers a clear, practical overview of the major eSignature types used in eConsent — ranging from simple electronic signatures to fully qualified electronic signatures — and explains when each is appropriate.
EPRO RESOURCES
-
Review the capabilities of this collection of ePRO applications, available on both web and mobile platforms, for enhancing hybrid or decentralized clinical trial experiences.
-
Learn how eConsent digitalizes the trial participant consent process through increasingly simplified models designed to improve comprehension and boost engagement.
-
Dr. Anthony Everhart (Clinical VP, Signant Health) and Tim Meyer (Professor, University College London) discuss opportunities for increasing the usefulness of PROMs.